Clinical Trial Update: AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid [Phase 3]

View source ↗

Summary

Phase 3 trial update for lecanemab in preclinical Alzheimer's disease with elevated amyloid, including early preclinical stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Lecanemab (lecanemab)

Snippet

Sponsor: Eisai Inc. | Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING